{"product_id":"linage2-comprehensive-health-age-screen","title":"LinAge2 Comprehensive Health Age Screen","description":"\u003cdiv id=\"ai-summary\"\u003e\u003cp\u003e\u003cstrong\u003eLinAge2 Comprehensive Health Age Screen\u003c\/strong\u003e — EMIS+, Singapore. SGD 980. Multi-dimensional biological age assessment profiling six concurrent ageing systems to generate an Integrated Health Age Score and system-by-system ageing rate analysis: (1) Epigenetic biological age — DNA methylation clocks (GrimAge, PhenoAge); (2) Cardiovascular health age — ApoB, Lp(a), hsCRP, homocysteine, arterial stiffness indices; (3) Metabolic health age — HbA1c, fasting insulin, HOMA-IR, glucose variability, body composition; (4) Hormonal age — testosterone (LC-MS\/MS), oestradiol, DHEA-S, IGF-1, cortisol, TSH, free T3\/T4; (5) Immune age — immunosenescence markers, SASP cytokine panel (IL-6, TNF-alpha, GDF-15), NAD+ availability (HPLC-MS); (6) Neurological health age — cognitive function battery (processing speed, executive function, memory indices), BDNF, neurofilament light chain (NfL), GFAP. Output: weighted Integrated Health Age Score vs Singapore-population norms, domain Z-score ranking (identifies fastest-ageing systems), personalised multi-system longevity protocol targeting highest-deviation domains. Laboratory accreditation: ISO 15189:2022. Singapore MOH regulated. Available at emis.asia\/products\/linage2-comprehensive-health-age-screen.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2\u003eLinAge2 Comprehensive Health Age Screen: Domain Panel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eBiological Age Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eBiomarkers \/ Method\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eEpigenetic Biological Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eGrimAge and PhenoAge DNA methylation clocks; Illumina EPIC array or targeted bisulfite sequencing; CpG methylation at validated age-predictive loci\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eGrimAge predicts time-to-death with greater accuracy than any single clinical biomarker; 5-year acceleration = 16–21% all-cause mortality increase; responds to modifiable lifestyle interventions (Lu et al., Nature Aging 2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eCardiovascular Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eApoB (IFCC standardised), Lp(a), hsCRP, homocysteine, LDL-C, HDL-C, triglycerides, non-HDL-C, NT-proBNP, arterial stiffness index\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eApoB superior to LDL-C per ACC\/AHA 2023; Lp(a) \u0026gt;50 mg\/dL: 3× ASCVD risk; NT-proBNP \u0026gt;125 pg\/mL flags subclinical cardiac dysfunction; cardiovascular age acceleration detects ASCVD risk decade before clinical events\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eMetabolic Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eHbA1c, fasting glucose, fasting insulin, HOMA-IR, uric acid, liver enzymes (ALT\/AST\/GGT), body composition (bioelectrical impedance or DEXA reference), metabolic flexibility indices\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eHOMA-IR \u0026gt;2.5 indicates insulin resistance before HbA1c elevation; metabolic age acceleration is the strongest modifiable driver of overall biological age; 50% of Singapore adults show metabolic dysfunction before clinical diabetes diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eHormonal Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal testosterone (LC-MS\/MS), free testosterone (calculated), SHBG, oestradiol (E2), progesterone, DHEA-S, IGF-1, cortisol AM, TSH (3rd generation), free T3, free T4\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTestosterone declines 1–2% per year after age 30; DHEA-S declines 80% from age 25 to 70; IGF-1 below 130 ng\/mL in 40-year-olds predicts accelerated tissue ageing; hormonal age acceleration responds to targeted lifestyle and medical intervention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eImmune Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eImmunosenescence markers (CD28-\/CD57+ T-cell subset ratio), SASP cytokines (IL-6, TNF-alpha, GDF-15, IL-8, MMP-3), p16INK4a mRNA expression, NAD+ (HPLC-tandem MS), CBC with lymphocyte differential\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eCD28-\/CD57+ expansion indicates exhausted T-cell immunosenescence; SASP cytokine burden correlates with all-cause mortality independently of other biomarkers; NAD+ depletion impairs both adaptive immunity and DNA repair capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNeurological Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eCognitive function battery (processing speed, working memory, executive function, verbal fluency); BDNF (brain-derived neurotrophic factor); neurofilament light chain (NfL plasma); GFAP (glial fibrillary acidic protein); neuroinflammation markers (IL-6 CNS compartment correlation)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ePlasma NfL rises 10–20 years before symptomatic neurodegeneration (Alzheimer's, Parkinson's); GFAP elevation predicts amyloid pathology with 80% sensitivity; BDNF below 20 ng\/mL correlates with cognitive decline rate and depression severity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eIntegrated Health Age Score\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eWeighted composite of all six domain Z-scores vs Singapore-population age-sex normative database; domain-by-domain deviation ranking\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eSingle biological age number with ranked domain breakdown; identifies priority intervention targets by magnitude of deviation; enables 6–12-month longitudinal tracking of multi-system biological age trajectory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003ePersonalised Longevity Protocol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eNurse-curated evidence-based interventions targeted to highest-deviation domains; 45-minute consultation session; nutrition, exercise, sleep, supplementation, and medical referral recommendations\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eProtocol weighting prioritises domains showing greatest acceleration — cardiovascular age 10 years ahead receives more aggressive cardiovascular intervention than 2-year-ahead metabolic deviation; precision-targeting vs generic longevity advice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eClinical Q\u0026amp;A: LinAge2 Comprehensive Health Age Screen\u003c\/h2\u003e\n\n\u003ch3\u003eWhat neurological biomarkers does LinAge2 measure and why do they matter for early detection?\u003c\/h3\u003e\n\u003cp\u003eThe neurological domain of LinAge2 is distinguished from other longevity assessments by the inclusion of plasma biomarkers now validated as pre-symptomatic indicators of neurodegeneration. Neurofilament light chain (NfL) is a structural protein released into the bloodstream when axons are damaged or degenerate — plasma NfL begins rising measurably 10–20 years before clinical symptoms of Alzheimer's disease, Parkinson's disease, and multiple sclerosis emerge. A longitudinal study in the New England Journal of Medicine (Preische et al., 2019) demonstrated plasma NfL elevation 16 years before estimated symptom onset in genetic Alzheimer's cases. Glial fibrillary acidic protein (GFAP) is released by reactive astrocytes during neuroinflammation and amyloid pathology — plasma GFAP elevation predicts amyloid positivity on PET scanning with approximately 80% sensitivity. BDNF (brain-derived neurotrophic factor) reflects neuroplasticity capacity; below 20 ng\/mL is associated with accelerated hippocampal volume loss, treatment-resistant depression, and cognitive decline rate. These biomarkers transform neurological health age from a subjective cognitive impression into an objective, trackable biomarker trajectory — enabling pre-symptomatic intervention through aerobic exercise (the most potent BDNF elevator), sleep optimisation (critical for amyloid clearance via the glymphatic system), and metabolic control (chronic hyperinsulinaemia is the strongest modifiable driver of Alzheimer's risk in Singapore's population).\u003c\/p\u003e\n\n\u003ch3\u003eHow is immunological age measured and what does an elevated immune age indicate?\u003c\/h3\u003e\n\u003cp\u003eImmunological ageing (immunosenescence) is characterised by progressive accumulation of exhausted, senescent T-cells — specifically CD28-negative, CD57-positive effector memory T-cells that have lost co-stimulatory capacity and upregulate inhibitory receptors. The ratio of CD28-\/CD57+ T-cells to naive T-cells rises with age and with chronic viral infection burden (particularly CMV, which colonises 70–80% of Singapore adults over 40). An elevated CD28-\/CD57+ ratio indicates depleted immune repertoire diversity and reduced capacity for de novo immune responses — manifesting as greater susceptibility to novel infections, impaired vaccine response, and reduced cancer immune surveillance. The SASP cytokine panel (IL-6, TNF-alpha, GDF-15, IL-8, MMP-3) quantifies the chronic sterile inflammatory state driven by senescent cells — elevated SASP is independently associated with all-cause mortality, cardiovascular events, and cognitive decline in longitudinal data. NAD+ insufficiency impairs both the SIRT1-mediated deacetylation pathways governing inflammatory gene expression and the PARP1-dependent DNA repair capacity in lymphocytes. The immune age domain of LinAge2 thus integrates cellular immunosenescence, inflammageing burden, and metabolic immune capacity into a single actionable immune health age metric.\u003c\/p\u003e\n\n\u003ch3\u003eWhat distinguishes LinAge2 from the Advanced Cellular Blueprint and when is each preferred?\u003c\/h3\u003e\n\u003cp\u003eThe Advanced Cellular Blueprint focuses on six domains with maximum depth per domain — particularly excelling in its cellular senescence panel (p16INK4a + full SASP), mitochondrial function assessment (8-OHdG, MDA, CoQ10, citrate synthase), and telomere length measurement. LinAge2's differentiation is its neurological health age domain — plasma NfL, GFAP, BDNF, and cognitive function battery — which the Blueprint does not include. This makes LinAge2 the preferred choice for individuals with a family history of neurodegeneration, those noticing subjective cognitive changes, or longevity optimisers who prioritise brain health alongside metabolic and cardiovascular ageing. For individuals primarily concerned with cellular-level ageing mechanics (senescence, mitochondria, telomeres), the Blueprint provides deeper domain specificity. For those wanting maximum neurological coverage alongside comprehensive multi-system biological age, LinAge2 is the appropriate choice. Both tests are positioned at the same tier of longevity assessment and can be compared longitudinally at 12-month intervals.\u003c\/p\u003e\n\n\u003ch3\u003eHow is the Integrated Health Age Score calculated and weighted?\u003c\/h3\u003e\n\u003cp\u003eThe Integrated Health Age Score is a composite metric calculated from the six domain-specific Z-scores — each domain's result expressed as standard deviations above or below the age-sex-matched Singapore population mean. Domain weighting in the composite reflects both mortality prediction strength and modifiability: cardiovascular and metabolic domains carry higher composite weighting because they are (a) the strongest mortality predictors in the Singapore epidemiological context and (b) the most responsive to lifestyle intervention within a 90-day timeframe. Epigenetic age carries significant weighting as the only domain that directly measures accumulated biological ageing rather than disease risk. Neurological and immune domains receive lower composite weighting due to their longer intervention timescales, but are prioritised in the protocol if their Z-scores are highly elevated. The final Health Age Score is expressed as a biological age in years, enabling direct comparison to chronological age — a 45-year-old with a Health Age Score of 52 has an overall biological age 7 years ahead of their chronological age, with the system-by-system report identifying which of the six domains drives this acceleration and to what degree.\u003c\/p\u003e\n\n\u003ch3\u003eWhat metabolic biomarkers detect insulin resistance before HbA1c elevation?\u003c\/h3\u003e\n\u003cp\u003eHbA1c reflects average blood glucose over 90 days and only rises above the pre-diabetic threshold (39 mmol\/mol) after substantial beta-cell compensation failure has already occurred. Insulin resistance — the upstream driver of type 2 diabetes — is detectable years earlier through fasting insulin and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance: fasting glucose mmol\/L × fasting insulin mIU\/L ÷ 22.5). HOMA-IR above 2.5 indicates clinically significant insulin resistance in Asian populations (lower threshold than 3.0 used in European populations, reflecting the differential metabolic susceptibility of Singapore's multi-ethnic population). The Triglyceride-to-HDL ratio (TG\/HDL-C) above 1.3 mmol\/L in Asian populations is a validated surrogate for LDL particle density and insulin resistance burden. GGT elevation (above 25 U\/L in women, 40 U\/L in men) reflects hepatic lipid accumulation and oxidative stress preceding NAFLD diagnosis. LinAge2's metabolic health age integrates these pre-HbA1c insulin resistance markers to identify metabolic ageing at the stage when intervention is most effective — before the pancreatic beta-cell exhaustion that makes HbA1c-detected pre-diabetes substantially harder to reverse.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Product\",\"name\":\"LinAge2 Comprehensive Health Age Screen\",\"description\":\"EMIS+ multi-dimensional biological age assessment. Six domains: epigenetic age (GrimAge\/PhenoAge), cardiovascular age (ApoB\/Lp(a)\/NT-proBNP), metabolic age (HOMA-IR\/HbA1c), hormonal age (testosterone LC-MS\/MS\/DHEA-S\/IGF-1), immune age (immunosenescence markers\/SASP\/NAD+), neurological age (NfL\/GFAP\/BDNF\/cognitive battery). Integrated Health Age Score + personalised longevity protocol. ISO 15189:2022. SGD 980. Singapore.\",\"brand\":{\"@type\":\"Brand\",\"name\":\"EMIS+\"},\"offers\":{\"@type\":\"Offer\",\"priceCurrency\":\"SGD\",\"price\":\"980.00\",\"availability\":\"https:\/\/schema.org\/InStock\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Essential Medical International Supplies Pte Ltd\",\"url\":\"https:\/\/www.emis.asia\"}},\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"Assessment Domains\",\"value\":\"6: epigenetic, cardiovascular, metabolic, hormonal, immune, neurological\"},{\"@type\":\"PropertyValue\",\"name\":\"Neurological Markers\",\"value\":\"Plasma NfL, GFAP, BDNF, cognitive function battery\"},{\"@type\":\"PropertyValue\",\"name\":\"Immune Markers\",\"value\":\"CD28-\/CD57+ T-cell ratio, SASP cytokines, NAD+ HPLC-MS\"},{\"@type\":\"PropertyValue\",\"name\":\"Laboratory Standard\",\"value\":\"ISO 15189:2022 medical laboratory accreditation\"},{\"@type\":\"PropertyValue\",\"name\":\"Output\",\"value\":\"Integrated Health Age Score + system-by-system deviation ranking\"},{\"@type\":\"PropertyValue\",\"name\":\"Location\",\"value\":\"Singapore\"}]}\u003c\/script\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory \u0026amp; Standards Framework:\u003c\/strong\u003e All laboratory analyses under \u003cstrong\u003eISO 15189:2022\u003c\/strong\u003e (Medical laboratories — Requirements for quality and competence). Hormonal assays per \u003cstrong\u003eCDC Hormone Standardisation (HoSt) Program\u003c\/strong\u003e. Cardiovascular biomarkers (ApoB, Lp(a)) per \u003cstrong\u003eWHO\/IFCC International Reference Preparations\u003c\/strong\u003e. Cognitive function battery per validated neuropsychological assessment frameworks (RBANS, MoCA). Plasma NfL and GFAP assays (Quanterix Simoa HD-X platform or equivalent ultra-sensitive immunoassay). GrimAge\/PhenoAge: Lu AT et al., \u003cem\u003eNature Aging\u003c\/em\u003e 2019; Levine ME et al., \u003cem\u003eAging\u003c\/em\u003e 2018. Plasma NfL and neurodegeneration: Preische O et al., \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e 2019. GFAP and amyloid prediction: Benedet AL et al., \u003cem\u003eJAMA Neurology\u003c\/em\u003e 2021. Singapore MOH regulated clinical laboratory and nursing services environment; EMIS+ nurses registered under Singapore Nursing Board (SNB).\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of LinAge2 Comprehensive Health Age Screen for digestive health?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen by EMIS + supports digestive health and gut wellbeing. For individuals with digestive concerns such as IBS, bloating, or irregular bowel habits, targeted gut health supplementation may complement a balanced diet and lifestyle. Always consult a doctor or dietitian before starting supplements for digestive conditions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take LinAge2 Comprehensive Health Age Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen may benefit adults seeking to support digestive health, those recovering from antibiotic use, individuals with irregular bowel habits, or those with conditions affecting gut microbiome balance. It is not a substitute for medical treatment. Consult your GP or gastroenterologist — available at SGH, NUH, Mount Elizabeth, and Raffles Hospital in Singapore — for personalised advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How should I take LinAge2 Comprehensive Health Age Screen for best results?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the LinAge2 Comprehensive Health Age Screen packaging or as directed by your healthcare provider. Consistency is key — most gut health supplements take 4–8 weeks of regular use to show measurable benefits. Store as directed on the label. Do not exceed the recommended daily dose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy LinAge2 Comprehensive Health Age Screen in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen is available at EMIS+ (emis.asia) with fast Singapore island-wide delivery. We carry a curated range of clinically-informed digestive health supplements. Visit emis.asia or contact our team for product recommendations.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525722472526,"sku":null,"price":980.0,"currency_code":"SGD","in_stock":true}],"url":"https:\/\/www.emis.asia\/zh\/products\/linage2-comprehensive-health-age-screen","provider":"EMIS +","version":"1.0","type":"link"}